immuno-oncology

News

Novartis returns PD-1 antibody rights to BeiGene

BeiGene confirmed today that Novartis has pulled out of a partnership on PD-1 inhibitor tislelizumab, two and half years after paying $650 million upfront for ex-China rig

News

'Inadvertent' leak teases survival benefit for Roche's TIGIT

In an unusual development, Roche has put out a statement this morning acknowledging an "inadvertent disclosure" of data from its SKYSCRAPER-01 study of anti-TIGIT drug tir

News

FDA places Gilead's CD47 drug on another clinical hold

Gilead is dealing with more turbulence in its development of CD47-targeting antibody magrolimab, with a partial clinical hold placed on the drug by the FDA in acute myeloi

News

Trial backs use of Cabometyx, Tecentriq in prostate cancer

Ipsen and Exelixis could expand the use of blockbuster oncology drug Cabometyx into prostate cancer, based on data from a phase 3 study – and help bring a cancer immunothe

News

Keytruda backed for 'basket' of new cancers via NHS

The UK's cost-effectiveness agency NICE has recommended MSD's PD-1 inhibitor Keytruda for a series of cancers based on genetic abnormalities known as microsatellite instab

News

Arcus and Gilead drop A2R drug for prostate cancer

Arcus and Gilead Sciences have decided not to continue the development of their A2 receptor antagonist etrumadenant in castration-resistant prostate cancer (CRPC) after an

Novartis returns PD-1 antibody rights to BeiGene

'Inadvertent' leak teases survival benefit for Roche's TIGIT

FDA places Gilead's CD47 drug on another clinical hold

Trial backs use of Cabometyx, Tecentriq in prostate cancer

Keytruda backed for 'basket' of new cancers via NHS

Arcus and Gilead drop A2R drug for prostate cancer

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

immuno-oncology

Editor's Picks